Company news
Shield Therapeutics Plc (LSE:STX) news
Shield Therapeutics Plc news releases on 6ix. Latest, Sep 4, 2024: Interim results
Press releases — page 2
Interim results
September 4, 2024
ACCRUFeR® Approved by Health Canada
August 27, 2024
Notice of interim results
August 14, 2024
Unaudited Q2 2024 Trading Update
July 24, 2024
$5.7m Milestone Monetization Agreement with AOP
July 3, 2024
Results of 2024 Annual General Meeting
June 20, 2024
New Drug Application for Accrufer® in South Korea
May 28, 2024
Hardman & Co: Shield Therapeutics (STX): Cash...
May 23, 2024
Audited results for the year ended 31 Dec 2023
May 10, 2024
Business Update for Q1 2024
April 30, 2024
Notice of Results
April 16, 2024
Unaudited Full Year Trading Update
February 21, 2024
Appointment of new Chief Financial Officer
January 9, 2024
Q3 2023 U.S. Commercial Highlights
December 7, 2023
Abstract to be presented at Healthcare Conference
October 20, 2023
Chief Financial Officer Transition
October 12, 2023
Result of REX Retail Offer
October 3, 2023
Successful completion of US$6.1m Equity Fundraise
September 28, 2023
Notice of Results and Change in reporting currency
September 6, 2023
Holding(s) in Company
July 24, 2023
Business Update and U.S. Q2 2023 Highlights
July 20, 2023
Results of 2023 Annual General Meeting
June 28, 2023
Grant of share options to the CEO
June 6, 2023
2022 Annual Report and 2023 AGM Notice
May 19, 2023
Rule 2.9 Announcement and TVR Update
May 9, 2023
Business Update and Unaudited Results
April 27, 2023
Appointment of Chief Commercial Officer
April 5, 2023
Block Listing 6 Monthly Return
March 31, 2023
Price Monitoring Extension
March 15, 2023
Total Voting Rights Update
February 28, 2023
Second Price Monitoring Extn
February 17, 2023
Full Year Trading Update
February 9, 2023
Hardman & Co Q&A on Shield Therapeutics...
January 23, 2023
Hardman & Co Research: Shield Therapeutics ...
January 13, 2023
Partial AOP Loan Conversion
January 9, 2023
Result of General Meeting & Open Offer
January 5, 2023
Publication of Circular &Notice of General Meeting
December 16, 2022
Successful completion of US$18.5m Equity Fundraise
December 13, 2022
Republic of Korea update
October 31, 2022
Shelf-life for Accrufer® extended to 48 months
October 27, 2022
Data presented at ACG Annual Scientific Meeting
October 24, 2022
Hardman & Co Research on Shield Therapeutic...
September 15, 2022
Half-year Report
September 8, 2022
Launch of new corporate brand and website
September 1, 2022
Notice of Interim Results
August 31, 2022
Hardman & Co: Q&A on Shield Therapeutic...
August 12, 2022
Grant of share options
August 9, 2022
Completion of Loan Agreement & Partial Conversion
August 1, 2022
Results of 2022 General Meeting
July 27, 2022
Shield Therapeutics (STX): Looking to accelerat...
July 26, 2022